Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia.
Gutman JA, Winters A, Kent A, Amaya M, McMahon C, Smith C, Jordan CT, Stevens B, Minhajuddin M, Pei S, Schowinsky J, Tobin J, O'Brien K, Falco A, Taylor E, Brecl C, Zhou K, Ho P, Sohalski C, Dell-Martin J, Ondracek O, Abbott D, Pollyea DA.
Gutman JA, et al. Among authors: tobin j.
Haematologica. 2023 Oct 1;108(10):2616-2625. doi: 10.3324/haematol.2023.282681.
Haematologica. 2023.
PMID: 37051756
Free PMC article.
Clinical Trial.